Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind,…

By Jin Li, S. Qin, R. Xu, T. Yau, B. Ma, H. Pan, Jianming Xu, Yuxian Bai, Y. Chi, Li-wei Wang and 10 more. The Lancet Oncology, 2015

751 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/92a8b7f83235a02f236a85fb7b13e99b841eb22f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. A. Bardelli

In Oncology

1. Fortunato Ciardiello

Citations in the corpus

• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “The multi-targeted kinase inhibitor regorafenib has reported activity versus placebo plus best supportive care in two phase III trials [297, 298].”